WEDNESDAY, August 26 | 6:30 - 9:30 PM (DINNER PROVIDED)

This short course will provide a brief overview of the organization of the immune system that will then serve as the basis for discussions of how the immune system can be modulated through biopharmaceutical intervention to either enhance anti-tumor immunity or suppress pathogenic inflammation. We will cover basic principles of immune-oncology (e.g., checkpoint blockade) and progress in targeting immune processes with small molecules and protein-based immunomodulatory therapies.

Topics to be Covered:

  • Basic principles of anti-tumor immune responses
  • Strategies to enhance anti-tumor T/NK cell activity (e.g., CAR T, checkpoint blockade)
  • Activation of innate cells to initiate anti-tumor immunity
  • Small molecule immuno-oncology targets


Bauler_TimothyTimothy Bauler, PhD, Assistant Professor, Biomedical Sciences, Western Michigan University School of Medicine

Tim Bauler is a full-time medical educator who teaches immunology and infectious disease in an integrated curriculum combining basic science with clinical applications. Tim received a PhD in Microbiology and Immunology from the University of Michigan after studying the role of protein tyrosine phosphatases in regulating proximal T cell signal transduction. His postdoctoral fellowship at Rocky Mountain Laboratories, NIAID, NIH, focused on the innate immune response to intracellular bacterial pathogens, including Salmonella Typhimurium and highly virulent Francisella tularensis which must be studied under Biosafety Level 3 containment.

Sunberg_ThomasThomas Sundberg, PhD, Senior Group Leader, Center for Development of Therapeutics, Broad Institute of MIT and Harvard

Tom Sundberg has expertise in chemical biology and translational immunology in the Center for Development of Therapeutics at the Broad Institute of MIT and Harvard. The focus of his work at CDoT is developing approaches to enhance anti-inflammatory functions of immune cells. As part of these efforts, he serves as a project lead for a collaboration with a biopharmaceutical industry partner developing first-in-class therapies for autoimmune/auto-inflammatory disorders. Tom received a PhD in chemical biology from the University of Michigan at Ann Arbor and upon its completion in 2010 was awarded the American Cancer Society Postdoctoral Fellowship at Yale University; in the course of the fellowship, he studied new chemical biology approaches to targeted protein degradation.

Back to Short Courses